| Literature DB >> 29615760 |
Anil Kumar1, Juan Jovel2, Joaquin Lopez-Orozco1, Daniel Limonta1, Adriana M Airo3, Shangmei Hou1, Iryna Stryapunina1, Chad Fibke3, Ronald B Moore4, Tom C Hobman5,6,7,8.
Abstract
Zika virus is a teratogenic mosquito-transmitted flavivirus that is associated with birth defects in newborns and Guillain-Barré syndrome in adults. The virus can also be sexually transmitted, but currently, very little is known about the cell types supporting virus replication and persistence in human testes. Using primary cell cultures, we observed that Sertoli but not Leydig cells are highly susceptible to Zika virus infection, a process that is dependent on the TAM family receptor Axl. In cell culture, Sertoli cells could be productively infected with Zika virus for at least 6-weeks. Infection of Sertoli cells resulted in dramatic changes to the transcriptional profile of these cells. The most upregulated mRNA in infected cells was basic fibroblast growth factor (FGF2), a cytokine that was found to enhance Zika virus replication and support viral persistence. Together these findings provide key insights into understanding how Zika virus persists in the male reproductive tract and in turn may aid in developing antiviral therapies or strategies to minimize sexual transmission of this pathogen.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29615760 PMCID: PMC5883016 DOI: 10.1038/s41598-018-23899-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Sertoli cells support high levels of ZIKV replication. (A) Primary human Sertoli and Leydig cells and the human A549 cell line were infected with ZIKV strain MR766 (MR) or PRVABC59 (PR) (MOI = 5) for 24, 48, 72 and 96 hours. At each time point, supernatants were harvested and viral titers were determined by plaque assay. (B–E) Cells were harvested at each time point and viral replication (B), Interferon-β (C), Interferon-λ2 (D) and OAS2 (E) mRNA levels were determined by qRT-PCR. (F) Sertoli cells seeded on coverslips were infected with ZIKV MR766 (MR) or PRVABC59 (PR) (MOI = 5) for 48 hours and then processed for indirect immunofluorescence using antibodies to ZIKV NS1 and GATA4 to identify infected cells expressing Sertoli markers. Nuclei were stained with DAPI. Representative images are shown. All values are expressed as mean ± standard error. N = 3.
Apoptosis in ZIKV-infected Sertoli and A549 cells.
| Sertoli Cells | ZIKV (+) | Casp-3 (+) | Casp-3 (+) in ZIKV (+) | |
|---|---|---|---|---|
| A | ||||
| 48 h | Mock | 1.2 ± 0.06 | 1.57 ± 0.03 | 0 |
| PR | 24.3 ± 0.92 | 1.13 ± 0.09 | 2.83 ± 0.49 | |
| MR | 44.57 ± 0.45 | 0.93 ± 0.09 | 1.43 ± 0.18 | |
| 72 h | Mock | 1.27 ± 0.07 | 1.73 ± 0.26 | 0 |
| PR | 29.37 ± 1.19 | 3.97 ± 0.23 | 9.43 ± 0.52 | |
| MR | 43.67 ± 2.66 | 2.63 ± 0.35 | 4.43 ± 0.27 | |
| B | ||||
|
|
|
|
| |
| 48 h | Mock | 0 | 0.67 ± 0.03 | 0 |
| PR | 52.73 ± 2.14 | 34.0 ± 2.68 | 41.8 ± 2.98 | |
| MR | 79.37 ± 0.99 | 29.43 ± 1.7 | 31.17 ± 1.35 | |
| 72 h | Mock | 0 | 0.83 ± 0.03 | 0 |
| PR | 48.07 ± 2.94 | 39.23 ± 2.92 | 58.57 ± 1.32 | |
| MR | 76.87 ± 1.33 | 59.07 ± 2.05 | 66.83 ± 1.79 | |
Sertoli cells (A) or A549 cells (B) were infected with ZIKV MR766 (MR) or PRVABC59 (PR) (MOI = 5) for 48 and 72 h. At each time point, cells were harvested and levels of viral infection and apoptosis were determined by FACS. Antibodies against ZIKV NS1 and activated caspase 3 were used to detect infected and apoptotic cells respectively. The percentage of cells positive for ZIKV antigen, activated caspase 3 or both markers are shown. All values are expressed as mean ± standard error. N = 3.
Figure 2Zika virus entry in Sertoli cells. Sertoli cells were pre-treated with antibodies to the indicated proteins (10 µg/ml) (A) or Axl inhibitor (R428) (B,D) for two hours and then infected with ZIKV PRVABC59 (PR) (A,B) or MR766 (MR) (D) (MOI = 1) for 48 hours after which total RNA was extracted and virus replication determined by qRT-PCR. ZIKV inocula ZIKV PRVABC59 (C) or MR766 (MR) (E) were incubated with indicated concentrations of duramycin at 37 °C for two hours and then used to infect Sertoli cells (MOI = 1) for 48 hours after which total RNA was extracted and virus replication determined by qRT-PCR. All values are expressed as mean ± standard error. *P < 0.05, **P < 0.01, **P < 0.001 (One-way ANOVA); N = 3.
Figure 3ZIKV persistence and deregulation mRNA transcripts in Sertoli cell. (A,B) Sertoli cells were infected with ZIKV MR766 (MR) or PRVABC59 (PR) (MOI = 0.5). Samples were harvested at the indicated time points after which viral titers (A) and replication (B) were determined by plaque assay and qRT-PCR respectively. (C,D) Sertoli cells were infected PRVABC59 (PR) (MOI = 5 or 0.5 for acute infection or persistent infection respectively) and harvested at 48-hours post-infection or 6-weeks post-infection. The mRNA transcript levels in each sample were determined by RNA-seq analysis. Heat maps representing the 20 transcripts with the largest variance subjected to hierarchical clustering at 48 h post-infection (C) and at 6-weeks post-infection (D) are shown. (E,F) Supernatants from Sertoli cells mock-treated or infected with ZIKV MR766 (MR) or PRVABC59 (PR) strains (MOI = 5) were subjected to ELISA to determine levels of FGF2 protein during acute (E) and persistent (F) infection. All values are expressed as mean ± standard error. *P < 0.05, **P < 0.01 (One-way ANOVA); N = 3.
GATA4 expression in ZIKV persistently-infected Sertoli cells.
| ZIKV (+) | GATA4 (+) | GATA4 (+) in ZIKV (+) | |
|---|---|---|---|
| PR | 14.87 ± 0.52 | 69.6 ± 6.50 | 90.77 ± 1.13 |
| MR | 18.53 ± 1.52 | 75.3 ± 8.37 | 87.03 ± 2.94 |
Sertoli cells were infected with ZIKV MR766 (MR) or PRVABC59 (PR) (MOI = 0.5). At 42-days post-infection, cells were harvested and the percentage of cells positive for viral antigen and GATA4 expression were determined by FACS. The percentage of cells positive for ZIKV NS1, GATA4 or both markers are shown. All values are expressed as mean ± standard error. N = 3.
Figure 4FGF-2 secretion from Sertoli cells supports ZIKV infection and persistence. (A–D) Sertoli cells were treated for 16-hours with anti-FGF2 antibody (A), recombinant human FGF2 (B), FGFR inhibitor BGJ398 (C) or Azithromycin (D) and then infected with ZIKV MR766 (MR) or PRVABC59 (PR) (MOI = 0.5). Cells were harvested 48-hours post-infection and viral replication was determined by qRT-PCR analyses of total RNA extracted from cells. (E) Sertoli cells persistently infected with ZIKV MR766 (MR) or PRVABC59 (PR) were treated with DMSO control, duramycin (0.1 uM), control antibody (10 µg/ml) or anti-FGF2 antibody (10 µg/ml) for 7-days and viral replication was determined by qRT-PCR analyses of total RNA extracted from cells. All values are expressed as mean ± standard error. *P < 0.05, **P < 0.01 (One-way ANOVA); N = 3.